Literature DB >> 24600122

Health economics and cost-effectiveness research with special reference to hemato-oncology.

Rajat Kumar1.   

Abstract

The cost of health care is increasing globally, especially in cancer. Health economics is an increasingly important field and medical professionals should have a working knowledge of the basis for health technology assessment such as cost-effectiveness analysis, cost utility analysis and cost benefit analysis. There are limited studies on health technology assessment regarding expensive therapies, primarily from high-income countries, but these cannot be applied to countries with different gross domestic product (GDP) and cost of health care delivery. There is a need to carry out health economics related research utilizing data from India. Whereas clinical trials establish the efficacy of new drugs in controlled environments, with strict inclusion and exclusion criteria, their transferability to the "real-world" situation is not always true. With the shifting of the global cancer burden to middle-income and lower middle-income countries, this field is going to assume greater importance in the future. Health economics research conducted in India may be of benefit to other countries with similar economies. The Armed Forces Medical Services of India, with a well-established system of assessing health outcomes, and robust system of accounting for expenses, can provide the lead for these studies.

Entities:  

Keywords:  Clinical effectiveness research; Health care expenditure; Health economics; Health technology assessment; Pharmaco-economics

Year:  2013        PMID: 24600122      PMCID: PMC3862911          DOI: 10.1016/j.mjafi.2013.06.003

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  17 in total

1.  What do we gain from the sixth stool guaiac?

Authors:  D Neuhauser; A M Lewicki
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

2.  Something old, something new, something borrowed...comparative effectiveness research: a policy perspective.

Authors:  Prasun Subedi; Eleanor M Perfetto; Riaz Ali
Journal:  J Manag Care Pharm       Date:  2011 Nov-Dec

3.  Why observational studies should be among the tools used in comparative effectiveness research.

Authors:  Nancy A Dreyer; Sean R Tunis; Marc Berger; Dan Ollendorf; Pattra Mattox; Richard Gliklich
Journal:  Health Aff (Millwood)       Date:  2010-10       Impact factor: 6.301

4.  External validity of randomised controlled trials: "to whom do the results of this trial apply?".

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

5.  Who pays for health care in Asia?

Authors:  Owen O'Donnell; Eddy van Doorslaer; Ravi P Rannan-Eliya; Aparnaa Somanathan; Shiva Raj Adhikari; Baktygul Akkazieva; Deni Harbianto; Charu C Garg; Piya Hanvoravongchai; Alejandro N Herrin; Mohammed N Huq; Shamsia Ibragimova; Anup Karan; Soon-man Kwon; Gabriel M Leung; Jui-fen Rachel Lu; Yasushi Ohkusa; Badri Raj Pande; Rachel Racelis; Keith Tin; Kanjana Tisayaticom; Laksono Trisnantoro; Quan Wan; Bong-Min Yang; Yuxin Zhao
Journal:  J Health Econ       Date:  2007-11-29       Impact factor: 3.883

6.  Criteria for deciding cost-effectiveness for expensive new anti-cancer agents.

Authors:  Rajiv Sarin
Journal:  J Cancer Res Ther       Date:  2008 Jan-Mar       Impact factor: 1.805

7.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Authors:  Fiona M Clement; Anthony Harris; Jing Jing Li; Karen Yong; Karen M Lee; Braden J Manns
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

8.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.

Authors:  A Cameron; M Ewen; D Ross-Degnan; D Ball; R Laing
Journal:  Lancet       Date:  2008-11-29       Impact factor: 79.321

9.  Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

Authors:  G J Ruiz-Argüelles; L C Tarin-Arzaga; M L Gonzalez-Carrillo; K I Gutierrez-Riveroll; R Rangel-Malo; C H Gutiérrez-Aguirre; O G Cantú-Rodríguez; D Gómez-Almaguer; S Giralt
Journal:  Bone Marrow Transplant       Date:  2008-07       Impact factor: 5.483

10.  Cost-benefit analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.